Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
Afinitor Extends PFS In Women With EGFR-2 Positive Disease
Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
CTEP-Approved Trials For the Month of June
FDA Approves Two Oral Drugs For Metastatic Melanoma
Trending Stories
- “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process - DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- How City of Hope is turning microbiome science into better cancer care
- FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market
